Article (Scientific journals)
Soluble biomarkers to predict clinical outcomes in non-small cell lung cancer treated by immune checkpoints inhibitors.
Ancel, Julien; Dormoy, Valérian; Raby, Béatrice Nawrocki et al.
2023In Frontiers in Immunology, 14, p. 1171649
Peer Reviewed verified by ORBi
 

Files


Full Text
Ancel et al. 2023.pdf
Author postprint (2.03 MB)
Download

All documents in ORBi are protected by a user license.

Send to



Details



Keywords :
circulating tumor (ctDNA); circulating tumor cell (CTC); immunotherapy; liquid biopsy; neutrophil lymphocyte ratio (NLR); non-small cell lung cancer (NSCLC); soluble biomarkers; Immune Checkpoint Inhibitors; Biomarkers, Tumor; Humans; Immune Checkpoint Inhibitors/therapeutic use; Lymphocytes/metabolism; Carcinoma, Non-Small-Cell Lung/drug therapy; Carcinoma, Non-Small-Cell Lung/metabolism; Lung Neoplasms/pathology; Carcinoma, Non-Small-Cell Lung; Lung Neoplasms; Lymphocytes; Immunology and Allergy; Immunology
Abstract :
[en] Lung cancer remains the first cause of cancer-related death despite many therapeutic innovations, including immune checkpoint inhibitors (ICI). ICI are now well used in daily practice at late metastatic stages and locally advanced stages after a chemo-radiation. ICI are also emerging in the peri-operative context. However, all patients do not benefit from ICI and even suffer from additional immune side effects. A current challenge remains to identify patients eligible for ICI and benefiting from these drugs. Currently, the prediction of ICI response is only supported by Programmed death-ligand 1 (PD-L1) tumor expression with perfectible results and limitations inherent to tumor-biopsy specimen analysis. Here, we reviewed alternative markers based on liquid biopsy and focused on the most promising biomarkers to modify clinical practice, including non-tumoral blood cell count such as absolute neutrophil counts, platelet to lymphocyte ratio, neutrophil to lymphocyte ratio, and derived neutrophil to lymphocyte ratio. We also discussed soluble-derived immune checkpoint-related products such as sPD-L1, circulating tumor cells (detection, count, and marker expression), and circulating tumor DNA-related products. Finally, we explored perspectives for liquid biopsies in the immune landscape and discussed how they could be implemented into lung cancer management with a potential biological-driven decision.
Disciplines :
Oncology
Author, co-author :
Ancel, Julien;  Inserm UMR-S1250, P3Cell, University of Reims Champagne-Ardenne, SFR CAP-SANTE, Reims, France ; Department of Respiratory Diseases, Centre Hospitalier Universitaire de Reims, Hôpital Maison Blanche, Reims, France
Dormoy, Valérian;  Inserm UMR-S1250, P3Cell, University of Reims Champagne-Ardenne, SFR CAP-SANTE, Reims, France
Raby, Béatrice Nawrocki;  Inserm UMR-S1250, P3Cell, University of Reims Champagne-Ardenne, SFR CAP-SANTE, Reims, France
Dalstein, Véronique;  Inserm UMR-S1250, P3Cell, University of Reims Champagne-Ardenne, SFR CAP-SANTE, Reims, France ; Department of Biopathology, Centre Hospitalier Universitaire de Reims, Hôpital Maison Blanche, Reims, France
Durlach, Anne;  Inserm UMR-S1250, P3Cell, University of Reims Champagne-Ardenne, SFR CAP-SANTE, Reims, France ; Department of Biopathology, Centre Hospitalier Universitaire de Reims, Hôpital Maison Blanche, Reims, France
Dewolf, Maxime;  Department of Respiratory Diseases, Centre Hospitalier Universitaire de Reims, Hôpital Maison Blanche, Reims, France
Gilles, Christine ;  Université de Liège - ULiège > Département des sciences biomédicales et précliniques
Polette, Myriam;  Inserm UMR-S1250, P3Cell, University of Reims Champagne-Ardenne, SFR CAP-SANTE, Reims, France ; Department of Biopathology, Centre Hospitalier Universitaire de Reims, Hôpital Maison Blanche, Reims, France
Deslée, Gaëtan;  Inserm UMR-S1250, P3Cell, University of Reims Champagne-Ardenne, SFR CAP-SANTE, Reims, France ; Department of Respiratory Diseases, Centre Hospitalier Universitaire de Reims, Hôpital Maison Blanche, Reims, France
Language :
English
Title :
Soluble biomarkers to predict clinical outcomes in non-small cell lung cancer treated by immune checkpoints inhibitors.
Publication date :
2023
Journal title :
Frontiers in Immunology
eISSN :
1664-3224
Publisher :
Frontiers Media S.A., Switzerland
Volume :
14
Pages :
1171649
Peer reviewed :
Peer Reviewed verified by ORBi
Funders :
URCA - Université de Reims Champagne-Ardenne [FR]
INSERM - Institut National de la Santé et de la Recherche Médicale [FR]
Funding text :
With financial support from ITMO Cancer of Aviesan within the framework of the 2021-2030 Cancer Control Strategy, on funds administered by Inserm, from the University of Reims Champagne Ardenne (URCA), France and Reims University Hospitals, France. AcknowledgmentsThe research effort associated with this review was funded in part by the Partenariat Hubert Curien-Tournesol. CG is a Senior Associate Researcher from FRS-FNRS (Belgium).
Available on ORBi :
since 07 September 2023

Statistics


Number of views
127 (3 by ULiège)
Number of downloads
24 (3 by ULiège)

Scopus citations®
 
5
Scopus citations®
without self-citations
5
OpenCitations
 
0

Bibliography


Similar publications



Contact ORBi